The privately held company incorporated earlier this year (2020) has said that it was awarded $354 million in federal funding to make raw ingredients used to treat patients infected with COVID-19. The company hadn’t manufactured or shipped any drugs before receiving the Government Contract. (Under the terms of the contract the total value could reach as high as $812 million).